- Home
- RNTX
as 06-20-2025 3:41pm EST
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 40.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 33.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.35 - $4.40 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Rein Therapeutics Inc. Common Stock News
RNTX Breaking Stock News: Dive into RNTX Ticker-Specific Updates for Smart Investing
PR Newswire
25 days ago
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
PR Newswire
a month ago
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
PR Newswire
a month ago
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
PR Newswire
a month ago
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
PR Newswire
2 months ago
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
PR Newswire
2 months ago
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025
PR Newswire
2 months ago
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
PR Newswire
2 months ago
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
Compare RNTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNTX Rein Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.